<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02790853</url>
  </required_header>
  <id_info>
    <org_study_id>2014-0831</org_study_id>
    <secondary_id>NCI-2018-02554</secondary_id>
    <secondary_id>2014-0831</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02790853</nct_id>
  </id_info>
  <brief_title>Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders</brief_title>
  <official_title>Multimodal Imaging for Surveillance of Patients With Oral Potentially Malignant Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This early phase I trial studies how well multimodal imaging works for surveillance in
      patients with oral potentially malignant disorders. New types of imaging devices may help
      doctors decide if a lesion in the mouth is pre-cancerous or cancerous.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare standard white light examination to multimodal imaging for detection of high
      grade dysplasia and carcinoma during follow-up examinations of patients with oral potentially
      malignant disorders (OPMD).

      SECONDARY OBJECTIVES:

      I. To determine qualitative and quantitative diagnostic assessment of patients who agree to
      undergo imaging and have images of sufficient quality.

      II. To compare expression of molecular biomarkers to results from white light examination,
      multimodal imaging and pathologic assessment in a subset of patients who have invasive
      biopsies or resection.

      III. To compare cytologic results from brush biopsy specimens to white light examination and
      multimodal imaging results.

      OUTLINE:

      Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with
      proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and
      incisional biopsy. Procedures are repeated every 3-4 months for 2 years.

      After completion of study treatment, patients are followed up at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2016</start_date>
  <completion_date type="Anticipated">May 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2026</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection of high grade dysplasia and carcinoma</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will compare standard white light examination to multimodal imaging for detection of high grade dysplasia and carcinoma during follow-up examinations of patients with oral potentially malignant disorders (OPMD).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic assessment</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will determine qualitative and quantitative diagnostic assessment of patients who agree to undergo imaging and have images of sufficient quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will compare expression of molecular biomarkers to results from white light examination, multimodal imaging and pathologic assessment in a subset of patients who have invasive biopsies or resection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytologic results</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will compare cytologic results from brush biopsy specimens to white light examination and multimodal imaging results.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Dysplasia</condition>
  <condition>Lip and Oral Cavity Carcinoma</condition>
  <condition>Oral Disorder</condition>
  <condition>Premalignant Lesion</condition>
  <arm_group>
    <arm_group_label>Diagnostic (multimodal imaging, biopsy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo PS2.1/PS3 imaging and high-resolution microendoscope imaging with proflavine hemisulfate applied to the mucosa. Patients also undergo brush biopsy and incisional biopsy. Procedures are repeated every 3-4 months for 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biopsy</intervention_name>
    <description>Undergo brush biopsy and incisional biopsy</description>
    <arm_group_label>Diagnostic (multimodal imaging, biopsy)</arm_group_label>
    <other_name>Bx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Fluorescence Imaging</intervention_name>
    <description>Undergo PS2.1/PS3 imaging</description>
    <arm_group_label>Diagnostic (multimodal imaging, biopsy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>High-Resolution Microendoscopy</intervention_name>
    <description>Undergo HRME imaging</description>
    <arm_group_label>Diagnostic (multimodal imaging, biopsy)</arm_group_label>
    <other_name>HRME</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proflavine Hemisulfate</intervention_name>
    <description>Applied on mucosa</description>
    <arm_group_label>Diagnostic (multimodal imaging, biopsy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who are willing to participate.

          -  Adult subjects with: a. clinically evident oral premalignant lesion (OPL) or
             suspicious oral mucosal lesion. or b. pathologic diagnosis of dysplasia or c. history
             of resected oral cancer or d. oral potentially malignant disorder (OPMD) or e. history
             of tobacco and/or alcohol exposure.

          -  Ability to understand and willingness to sign a written informed consent document
             (ICD).

        Exclusion Criteria:

          -  Known allergy to proflavine or acriflavine.

          -  Pregnant females.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Gillenwater</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Gillenwater</last_name>
    <phone>713-792-8441</phone>
    <email>agillenw@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann M. Gillenwater</last_name>
      <phone>713-792-8841</phone>
    </contact>
    <investigator>
      <last_name>Ann M. Gillenwater</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 26, 2016</study_first_submitted>
  <study_first_submitted_qc>May 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2016</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proflavine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

